Drug Trial News

RSS

$SGLT2 inhibitors reduce cardiovascular events among heart failure patients with mildly reduced and preserved ejection fraction$

SGLT2 inhibitors reduce cardiovascular events among heart failure patients with mildly reduced and preserved ejection fraction

An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure patients with mildly reduced and preserved ejection fraction.

28 Aug 2022

Gout medicine fails to improve cardiovascular outcomes in patients with ischemic heart disease

The gout medicine allopurinol has failed to reduce the primary endpoint of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death in patients with ischaemic heart disease, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.

28 Aug 2022

High-dose influenza vaccination in older adults leads to reductions in hospitalizations, all-cause mortality

In an innovative, pragmatic randomized trial, high-dose influenza vaccination in older adults was associated with a reduction in the risk of death by 49% and in the incidence of hospitalization for influenza or pneumonia by 64% compared with standard-dose vaccination.

28 Aug 2022

Adding acetazolamide to intravenous loop diuretics decreases congestion in patients with acute decompensated heart failure

Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients with acute decompensated heart failure, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.

28 Aug 2022

Sacubitril/valsartan does not change cognitive function in patients with heart failure

Sacubitril/valsartan does not change cognitive function, compared with valsartan, in patients with heart failure and mildly reduced or preserved ejection fraction, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.

26 Aug 2022

New study investigates a potential treatment for people diagnosed with monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox.

25 Aug 2022

Glucokinase activator AZD1656 shows potential benefit for diabetics with moderate to severe COVID-19

A new study examines the potential benefit of the glucokinase activator molecule AZD1656 in the ARCADIA trial.

23 Aug 2022

Clinical trial offers the best treatment option for patients with sight loss as a result of diabetes

A new clinical trial researching treatment for patients with sight loss as a result of diabetes has shown a type of laser treatment to be both cost effective and non-invasive, offering the best option for patients and healthcare providers.

23 Aug 2022

Scientists begin phase 2 clinical trials of lupus pill

Lupus is an autoimmune disease that attacks organs and can be fatal. There's no cure, so current treatments aim to limit damage and ameliorate symptoms.

22 Aug 2022

Monoclonal antibody decreases asthma attacks by 27% in children and adolescents of color

A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a National Institutes of Health clinical trial has found.

10 Aug 2022

Researchers identify novel molecular pathway that suppresses the spread of glioblastoma

UT Southwestern researchers have identified a molecular pathway responsible for the spread of glioblastoma to surrounding tissue in the brain, as well as an existing drug that curbed tumor growth in animal models.

10 Aug 2022

Next-generation monoclonal antibody prevents malaria

Researchers investigate the pharmacokinetics and safety of L9LS, a monoclonal antibody to prevent malaria.

9 Aug 2022

Should pregnant women be included clinical trials?

The current study reports some of the scientific, ethical, and legal considerations that will support the inclusion of pregnant women in future research.

8 Aug 2022

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment.

8 Aug 2022

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.

8 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Monoclonal antibody protects U.S. adults from malaria, Phase 1 clinical trial shows

One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.

4 Aug 2022

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.

2 Aug 2022

New trial offers double the traditional course of antibiotics for patients with life threatening infections

Hospital patients who develop infections where 10% of sufferers die will be offered double the traditional course of antibiotics in a new trial.

1 Aug 2022

Previous
1
...
43
44
45
46
47
48
49
...
1156
Next

Drug Trial News

SGLT2 inhibitors reduce cardiovascular events among heart failure patients with mildly reduced and preserved ejection fraction

Gout medicine fails to improve cardiovascular outcomes in patients with ischemic heart disease

High-dose influenza vaccination in older adults leads to reductions in hospitalizations, all-cause mortality

Adding acetazolamide to intravenous loop diuretics decreases congestion in patients with acute decompensated heart failure

Sacubitril/valsartan does not change cognitive function in patients with heart failure

New study investigates a potential treatment for people diagnosed with monkeypox

Glucokinase activator AZD1656 shows potential benefit for diabetics with moderate to severe COVID-19

Clinical trial offers the best treatment option for patients with sight loss as a result of diabetes

Scientists begin phase 2 clinical trials of lupus pill

Monoclonal antibody decreases asthma attacks by 27% in children and adolescents of color

Researchers identify novel molecular pathway that suppresses the spread of glioblastoma

Next-generation monoclonal antibody prevents malaria

Should pregnant women be included clinical trials?

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Monoclonal antibody protects U.S. adults from malaria, Phase 1 clinical trial shows

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

New trial offers double the traditional course of antibiotics for patients with life threatening infections

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News